Comparison Between Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers for Incidence of Lung Cancer: A Retrospective Study.
ace (angiotensin converting enzyme)
angiotensin receptor blockers
association
lung cancer
renin angiotensin alderosterone system
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
01 May 2021
01 May 2021
Historique:
entrez:
7
6
2021
pubmed:
8
6
2021
medline:
8
6
2021
Statut:
epublish
Résumé
Angiotensin-converting enzyme inhibitor (ACEI) and angiotensin II receptor blockers (ARBs) are taken as the first treatment option for hypertensive patients. The various global trials have suggested that ACEIs and ARBs may increase risk of lung cancer; however, the results are contradictory and there is no local study available. This study is conducted to compare the incidence of lung cancers in patients on ACEIs and ARBs. This retrospective study, conducted in a major cardiology unit of a tertiary care hospital in Pakistan, included patients diagnosed with hypertension, between 2005 and 2010, who were prescribed either ACEIs or ARBs. During the period of 2005 to 2010, 47,823 naïve hypertensive patients were reported in the outpatient department of the cardiology unit. Of which, 22,241 were prescribed ACEI and 25,582 were prescribed ARBs. After sorting patient data based on our inclusion criteria, n = 14,891 participants were included in the ACEI group and n = 19,112 participants were included in the ARB group. The incidence of lung cancer in the ACEI and ARB group was n = 165 and n = 160, respectively. In this study, the overall incidence rates of lung cancer in the ACEI and ARB cohorts were 12.2 and 16.6 per 10,000 person-years, respectively. The hazard ratio was 1.32 (95% confidence interval: 1.06-1.64; p-value: 0.01). In this study, the incidence of lung cancer was relatively more among people using ACEIs than ARBs. Hence, patients undergoing long-term treatment with ACEIs need regular follow-up and proper scanning to avoid grave complications.
Identifiants
pubmed: 34094750
doi: 10.7759/cureus.14788
pmc: PMC8168993
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e14788Informations de copyright
Copyright © 2021, Kumar et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Clin Oncol. 2007 Feb 10;25(5):472-8
pubmed: 17290054
Eur Respir J. 1993 Apr;6(4):576-87
pubmed: 8387934
Lancet Oncol. 2011 Jan;12(1):65-82
pubmed: 21123111
Hippokratia. 2007 Jul;11(3):124-8
pubmed: 19582206
Endocr Rev. 2003 Jun;24(3):261-71
pubmed: 12788798
BMJ. 2018 Oct 24;363:k4209
pubmed: 30355745
Circ Cardiovasc Qual Outcomes. 2021 Jan;14(1):e006687
pubmed: 33435729
J Hypertens. 2011 Apr;29(4):623-35
pubmed: 21358417
Lancet. 1998 Jul 18;352(9123):179-84
pubmed: 9683206
Trends Cardiovasc Med. 2020 Apr;30(3):160-164
pubmed: 31521481
Cancers (Basel). 2020 Mar 21;12(3):
pubmed: 32245239
J Renin Angiotensin Aldosterone Syst. 2020 Oct-Dec;21(4):1470320320981321
pubmed: 33325306
Curr Pharm Des. 2003;9(25):2036-42
pubmed: 14529414
Jpn J Pharmacol. 2001 Dec;87(4):318-26
pubmed: 11829151
J Am Heart Assoc. 2015 Dec 07;4(12):
pubmed: 26643500